Careers  |  Sign In  |  Register  |   Twitter

Drug Approved for Kidney Cancer May Stave Off Relapses of Ovarian Cancer

An article in The New York Times reports that “Women with ovarian cancer may be able to stave off relapses for an extra half-year or so by taking a drug already approved to treat kidney cancer.” The drug, pazopanib, was given to women as a maintenance therapy after they successfully completed chemotherapy. The study found that “For those who received the drug, the median time before the cancer worsened was 17.9 months, compared with 12.3 months for those given a placebo.” GlaxoSmithKline, manufactures the drug, said it will apply for approval for ovarian cancer.

Read it in The New York Times.